Antiretroviral Therapy in Children: Recent Advances
- First Online:
- 499 Downloads
Availability and successful use of various antiretroviral drugs has transformed HIV/AIDS from an incurable to a treatable chronic condition. The antiretroviral therapy can successfully suppress viral replication and preserve the immune system for many years. The implementation of antiretroviral therapy program in resource limited settings using the ‘public health approach’ of the World Health Organization has had a dramatic impact on the lives of millions of HIV infected individuals. Antiretroviral therapy (ART) in children has many challenges: use of appropriate formulations, regular need for modification of doses as the child grows, adherence issues, etc. To reduce the high morbidity and mortality in HIV infected children, it is currently recommended that all HIV infected children less than 24 mo should receive ART; in older children the indications are based on clinical and/or immunological criteria. Highly active antiretroviral therapy regimens include at least 3 antiretroviral drugs. The first line therapy recommended for children is a combination of two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor. Infants who have had exposure to nevirapine should receive a combination of two nucleoside reverse transcriptase inhibitors and a protease inhibitor; the protease inhibitor of choice is ritonavir boosted lopinavir. The success of therapy is dependent on >95 % adherence. The second line regimen, used when the first line therapy fails, is based on a protease inhibitor. The ongoing research focuses on simplification of regimen, discovery of more potent drugs, availability of more pediatric formulations, treatment of drug resistant strains etc. The optimal indications for initiation of therapy in children, are also being studied.
KeywordsAntiretroviral therapy Children HIV/AIDS Recent advances
- 4.Bartlett JG, Gallant JE. Medical management of HIV infection. Baltimore: Johns Hopkins Medicine Health Publishing Business Group;2004; pp 49.Google Scholar
- 7.World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach - 2010 revision. Geneva 2010.Google Scholar
- 9.Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 11, 2011; pp 1–268.Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf Accessed (September 5, 2011).
- 10.Guidelines for HIV care and treatment in Infants and Children. November 2006. published by IAP and NACO, available on www.nacoonline.org.
- 12.Palumbo P, Violari A, Lindsey L, et al. NVP- vs LPV/r-based ART among HIV + infants in resource-limited settings: the IMPAACT P1060 trial [abstract no.129LB]. 18th Conference on Retroviruses and Opportunistic Infections;2011 Feb 27-Mar 2; Boston (MA).Google Scholar
- 13.The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011;11:273–83.CrossRefGoogle Scholar
- 15.World Health Organization. Rapid advice. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva: WHO; 2009.Google Scholar
- 21.McKinney Jr RE, Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: pediatric AIDS clinical trials group protocol P1021. Pediatrics. 2007;120:e416–23.PubMedCrossRefGoogle Scholar
- 23.Fagard C, Oxenius A, Günthard H, et al; Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med. 2003;163:1220–6.Google Scholar
- 31.Palacios GC, Sanchez LM, Briones E, et al. Structured interruptions of highly active antiretroviral therapy in cycles of 4 wk off/12 wk on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. Int J Infect Dis. 2010;14:e34–40.PubMedCrossRefGoogle Scholar